Radionuclide

Linker

Trial/# of patients

Disease/endpoint

Results

survival

Author

²¹¹At

81-C6

Phase I/ 12

Primary brain tumors/dose finding

No grade 3 toxicity

OS:54 weeks for GBM

Zalutsky et al. [60]

²¹¹At

MX35 F(ab)2

Phase I / 9

Ovarian carcinoma/ dose absorption, safety

No adverse events

Not assessed

Andersson et al. [64]

²¹³Bi

HuM195

Phase I/ 18

AML

RR:14/18 no CR

Jurcic et al. [7]

²¹³Bi

HuM195

Phase I,II/ 20

AML sequential with ara-c/dose finding ,response rate

Limiting myelosupression with high dose/complete response  only with 2 highest doses

Rosenblat et al. [52]

²¹³Bi

Anti CD-20

Phase I/ 9

NHL/ Dose finding

Only 3 treated abstract form

Heeger et al. [53]

²¹³Bi

9.2.27

Phase I/ 16

Metastatic melanoma/ safety efficacy

Safe up to 450 mCi efficacious at 200 mCi

Allen et al. [56]